Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)
European Society of Cardiology (ESC) 2026
Congress Details
August 28 - 31, 2026
Munich, Germany
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Agenda
Filters
Therapeutic Areas
28 August, 2026
Presentation Type
Time
Location
Title
Presenter
Thibaud Damy
Hôpitaux Universitaires Henri-Mondor
Paris, France
30 August, 2026
Presentation Type
Time
Location
Title
Presenter
Olivier Lairez
Toulouse University Hospital
Tolouse, France
Presentation Type
Time
Location
Title
Presenter
Neha Pagidipati
Duke Clinical Research Institute
Durham, NC, USA
Presentation Type
Time
Location
Title
Presenter
Stéphanie Schwarting
Ludwig Maximillian University of Munich
Munich, Germany
Presentation Type
Time
Location
Title
Presenter
Yasuhiro Hamatani
Brigham and Women's Hospital
Boston, MA, USA
31 August, 2026
Presentation Type
Time
Location
Title
Presenter
Amira Zaroui
Assistance Publique-Hôpitaux de Paris
Paris, France
Related Materials
Transthyretin Amyloidosis (ATTR)
Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis
Journal of Clinical Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicenter Study
Annals of Medicine
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B
JACC: Advances
